Share on StockTwits
 

Investment analysts at Barclays assumed coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Wednesday, AnalystRatingsNetwork reports. The firm set an “overweight” rating and a $14.00 price target on the stock. Barclays’ target price would indicate a potential upside of 80.18% from the stock’s previous close.

Separately, analysts at Jefferies Group initiated coverage on shares of Trevena in a research note on Wednesday. They set a “buy” rating and a $11.00 price target on the stock.

Shares of Trevena (NASDAQ:TRVN) traded up 2.57% during mid-day trading on Wednesday, hitting $7.97. The stock had a trading volume of 415,924 shares. Trevena has a 52 week low of $6.00 and a 52 week high of $8.98. The stock’s 50-day moving average is $7.09 and its 200-day moving average is $7.09. The company’s market cap is $205.1 million.

Trevena, Inc (NASDAQ:TRVN) is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.